2024
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
Aragon-Ching J, Petrylak D, Sridhar S, Gupta S, Grivas P, Powles T, Gurney H, Jacob N, Tyroller K, Guenther S, Bellmunt J. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI). Journal Of Clinical Oncology 2024, 42: 600-600. DOI: 10.1200/jco.2024.42.4_suppl.600.Peer-Reviewed Original ResearchProgression-free survivalAdvanced urothelial carcinomaPlatinum-based chemotherapyBody mass indexHigher body mass indexLong-term outcomesOverall survivalLong-term safetyStandard of careMedian progression-free survivalProgression-free survival ratesAnalysis of long-term outcomesBSC-alone armMedian follow-upProlonged overall survivalLevel 1 evidenceLong-term efficacyInternational treatment guidelinesPost hoc analysisJAVELIN BladderMedian OSMetastatic UCOS ratesSafety populationData cutoff
2020
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Hussain M, Powles T, Albers P, Castellano D, Daneshmand S, Gschwend J, Nishiyama H, Oudard S, Tayama D, Davarpanah N, Degaonkar V, Shi Y, Mariathasan S, Grivas P, O'Donnell P, Rosenberg J, Geynisman D, Hoffman-Censits J, Petrylak D, Bellmunt J. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). Journal Of Clinical Oncology 2020, 38: 5000-5000. DOI: 10.1200/jco.2020.38.15_suppl.5000.Peer-Reviewed Original ResearchMuscle-invasive urothelial carcinomaDisease-free survivalNeoadjuvant chemoAdjuvant chemoPrimary endpointPrimary analysisECOG PS 0Interim overall survivalLymph node dissectionPD-L1 testingLevel 1 evidenceITT populationObs armPostsurgical radiationCheckpoint inhibitorsGastrointestinal toxicityMainstay treatmentNode dissectionPrimary resectionAdjuvant studiesOverall survivalPS 0Radical surgeryClinical factorsPrimary disease